Equities Analysts Offer Predictions for TOI Q2 Earnings

Key Points

• Noble Financial has estimated that Oncology Institute's Q2 2025 earnings per share (EPS) will be ($0.14), maintaining an "Outperform" rating with a price target of $8.00.
• Oncology Institute's stock experienced a 0.8% increase, opening at $3.68, with a notable range of a 52-week low of $0.13 and a high of $3.88.
• Insider sales saw Director Brad Hively reduce his holdings by approximately 76.61%, selling nearly 2 million shares, while total insider sales over the last 90 days amounted to over $13 million.

The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) - Research analysts at Noble Financial issued their Q2 2025 earnings per share estimates for shares of Oncology Institute in a research note issued to investors on Wednesday, July 23rd. Noble Financial analyst R. Leboyer anticipates that the company will post earnings per share of ($0.14) for the quarter. Noble Financial has a "Outperform" rating and a $8.00 price target on the stock. Noble Financial also issued estimates for Oncology Institute's Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.28) EPS.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter. Oncology Institute had a negative net margin of 15.38% and a negative return on equity of 445.02%. The company had revenue of $104.41 million during the quarter.

TOI has been the topic of several other research reports. B. Riley began coverage on Oncology Institute in a research report on Wednesday, July 16th. They set a "buy" rating and a $6.00 target price on the stock. BTIG Research began coverage on Oncology Institute in a research report on Thursday, May 15th. They issued a "buy" rating and a $7.00 target price for the company.

Oncology Institute Trading Up 2.0%

Shares of Oncology Institute stock traded up $0.08 on Monday, hitting $3.77. 373,557 shares of the company's stock traded hands, compared to its average volume of 1,408,039. Oncology Institute has a one year low of $0.13 and a one year high of $4.03. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.79 and a quick ratio of 1.59. The company has a fifty day moving average of $2.88 and a two-hundred day moving average of $1.93. The company has a market capitalization of $335.95 million, a price-to-earnings ratio of -5.40 and a beta of 0.02.

Insider Activity

In related news, Director Growth I. L.P. M33 sold 76,324 shares of the business's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $3.05, for a total transaction of $232,788.20. Following the transaction, the director owned 1,272,724 shares in the company, valued at $3,881,808.20. The trade was a 5.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Brad Hively sold 1,976,137 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $2.87, for a total value of $5,671,513.19. Following the transaction, the director owned 603,501 shares in the company, valued at approximately $1,732,047.87. This represents a 76.61% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,726,137 shares of company stock valued at $13,379,013. Corporate insiders own 8.50% of the company's stock.

Institutional Trading of Oncology Institute

Several large investors have recently bought and sold shares of the company. Jane Street Group LLC boosted its stake in Oncology Institute by 613.6% during the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock valued at $39,000 after purchasing an additional 109,769 shares during the last quarter. Virtu Financial LLC purchased a new stake in Oncology Institute during the 4th quarter valued at $41,000. Renaissance Technologies LLC boosted its stake in Oncology Institute by 7.1% during the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after purchasing an additional 12,000 shares during the last quarter. XTX Topco Ltd boosted its stake in Oncology Institute by 49.5% during the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock valued at $63,000 after purchasing an additional 18,448 shares during the last quarter. Finally, Citizens Financial Group Inc. RI purchased a new stake in Oncology Institute during the 1st quarter valued at $71,000. 36.86% of the stock is owned by institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.